卡培他滨联合长春瑞宾治疗晚期乳腺癌

目的:观察卡培他滨联合长春瑞宾对紫杉醇类和／或蒽环类耐药的晚期转移性乳腺癌的疗效及安全性。方法:对24例紫杉类和／或蒽环类耐药的、具有可测量病灶的晚期乳腺癌患者采用卡培他滨联合长春瑞宾进行治疗,21 d为1个周期,治疗2-6个周期。所有患者以往均接受过1种以上包括紫杉醇和／或多柔比星化疗方案的化疗。结果:24例患者中4例接受了2个周期化疗,5例完成3个周期化疗,12例完成4个周期的化疗,3例完成6个周期化疗。有效率(RR)为45．8％。不良反应14例。结论:卡培他滨联合长春瑞宾治疗晚期转移性乳腺癌的疗效确切且不良反应轻,有望成为紫杉醇类和／或蒽环类药物治疗失败的晚期转移性乳腺癌的理想方案。

Clinical Observation of Capecitabine Combined with Vinorelbine in Treatment for Advanced Breast Cancer

To observe the efficiency and safety on capecitabine combined with vinorelbine in the treatment of advanced and metastatic breast cancer (MBC). Method: Twenty-four patients with measurable MBC patients were received capecitabine com-bined vinorelbine treatment, a cycle was 21 days, treated 2-6 cycles. All patients had received more then one course including paclita-xel and/or adriamycin treatment. Result: Four patients received two cycles, five patients received three cycles, and twelve persons completed four cycles treatment, three persons completed six cycles. RR was 45.8%. There were 14 persons who had occurred side effects. Conclusion: The effect of combination of capecitabine and vinorelbine in the treatment of MBC is definite and the toxicity is small. It is possible for this regimen to become an ideal second line treatment for breast cancer patients in whom taxane and/or anthrac-icline treatment is failure.